A 24-week, Multinational, Multicentre, Randomised, Open Label, Parallel-group Treat-to-target Trial to Compare Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
Phase: PHASE4
Conditions: Diabetes, Type 2 Diabetes Mellitus
Sponsor: Novo Nordisk A/S

&RYHU3DJHIRU3URWRFRO
 
Sponsor name: 
Novo Nordisk A/S 
NCT number 
NCT02582242 
Sponsor trial ID: 
BIAsp-4200 
Official title of study: 
A 24-week, Multinational, Multicentre, Randomised, Open 
Label, Parallel-group Treat-to-target Trial to Compare Efficacy 
and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 
(Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes 
Inadequately Controlled With Basal Insulin 
Document date: 
13 September 2017 
 






5HGDFWHGSURWRFRO
,QFOXGHVUHGDFWLRQRISHUVRQDOLGHQWLILDEOHLQIRUPDWLRQRQO\




